Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases Journal Article


Authors: White, R. R.; Schwartz, L. H.; Munoz, J. A.; Raggio, G.; Jarnagin, W. R.; Fong, Y.; D'Angelica, M. I.; Kemeny, N. E.
Article Title: Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases
Abstract: Background and Objectives: Few studies have addressed the optimal duration of chemotherapy, particularly prior to liver resection for colorectal liver metastases (CLM). The purpose of this retrospective analysis was to evaluate time to maximal response in patients receiving systemic ± hepatic arterial infusion (HAI) chemotherapy alone for the treatment of CLM. Methods: We reviewed 35 patients with CLM on clinical trials of HAI floxuridine/ dexamethasone plus systemic oxaliplatin with 5-fluorouracil/leucovorin or irinotecan (PUMP + SYSTEMIC). We retrospectively identified 35 patients with CLM who received first-line systemic 5FU/leucovorin/oxaliplatin (FOLFOX) ± bevacizumab (SYSTEMIC) during the same time period. Measurable disease was evaluated on CT scans performed at 2-month intervals. The sum of the products of bi-dimensional tumor measurements for representative lesions was compared both to baseline imaging and between consecutive time points. Results: In responders to therapy, mean cumulative tumor reduction increased from 61% at 2 months to 73% at 4 months in the PUMP + SYSTEMIC group (P < 0.01) and from 39% to 56% in the SYSTEMIC group (P < 0.01). No significant incremental tumor reduction occurred between 4 and 6 months in either group. Conclusions: In responders to preoperative therapy, surgical resection should be considered after 2-4 months, when most patients have achieved maximal response. © 2008 Wiley-Liss, Inc.
Keywords: adult; cancer chemotherapy; clinical article; treatment outcome; aged; middle aged; retrospective studies; bevacizumab; fluorouracil; treatment duration; antineoplastic agents; liver neoplasms; chemotherapy; antineoplastic agent; colorectal cancer; computer assisted tomography; tumor volume; antineoplastic combined chemotherapy protocols; carcinoembryonic antigen; camptothecin; dexamethasone; retrospective study; time factors; irinotecan; colorectal neoplasms; liver metastasis; folinic acid; infusions, intra-arterial; liver resection; disease free interval; preoperative treatment; oxaliplatin; floxuridine; organoplatinum compounds; leucovorin; regional therapy
Journal Title: Journal of Surgical Oncology
Volume: 97
Issue: 7
ISSN: 0022-4790
Publisher: Wiley Blackwell  
Date Published: 2008-06-01
Start Page: 601
End Page: 604
Language: English
DOI: 10.1002/jso.21042
PUBMED: 18449915
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 5" - "Export Date: 17 November 2011" - "CODEN: JSONA" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Rebekah Ruth White
    10 White
  2. Lawrence H Schwartz
    306 Schwartz
  3. William R Jarnagin
    903 Jarnagin
  4. Yuman Fong
    775 Fong
  5. Nancy Kemeny
    543 Kemeny
  6. Jose A Munoz
    1 Munoz
  7. Greer Raggio
    2 Raggio